CUE

Cue Biopharma, Inc.

1.41 USD
+0.06 (+4.44%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Cue Biopharma, Inc. stock is down -13.5% since 30 days ago. The next earnings date is Aug 7, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 14.29% of the previous 6 June’s closed higher than May.

About Cue Biopharma, Inc.

Cue Biopharma, Inc. develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers.